We found that treatment with the CD47 antibody B6H12 altered gene expression in CD47-expressing triple-negative MDA-MB-231 breast carcinoma cells, resulting in suppression of breast cancer stem cell (bCSC) characteristics (Kaur et al., 2016). Here, CD47 is linked to breast cancer.